Naperville, IL -- (SBWire) -- 10/24/2014 --Reportstack, provider of premium market research reports announces the addition of Global ADHD Drugs Market 2014-2018 market report to its offering.

About ADHD
ADHD is a psychiatric disorder, which is mostly found in children. However, adults have also been reported to be diagnosed with ADHD. The patients with ADHD suffer from several problems including hyperactivity, impulsiveness, and lack of focus and concentration. The causes of ADHD are not known. It is believed to be linked with genetic and environmental causes. However, it has been reported to be related with the decrease in the extraneuronal levels of norepinephrine and dopamine. In addition, the patients have an abnormality in the brain structure. It is more prevalent in boys than girls. The management of ADHD is done by counseling, medications, and lifestyle changes.

Analysts forecast the Global ADHD Drugs market to grow at a CAGR of 5.33 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global ADHD Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of ADHD, which include:

Stimulants
Non-stimulants

Global ADHD Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global ADHD Drugs market landscape and its growth prospects in the coming years.

The report also includes a discussion of the key vendors operating in this market.

Key Regions
Americas
APAC
EMEA

Key Vendors
Eli Lilly and
Janssen
Novartis
Shire

Other Prominent Vendors

Actavis
Alcobra
Amarantus
Boehringer Ingelheim
Concordia
Curemark
GlaxoSmithKline
Hisamitsu
Impax
Intellipharmaceutics
Mylan
Neurovance
Noven
Par Pharmaceuticals
Sanofi
Shionogi
Sunovion
Teva
Tris Pharma

Market Driver
Presence of Unmet Need
For a full, detailed list, view our report

Market Challenge
Unknown Etiology
For a full, detailed list, view our report

Market Trend
Increase in Awareness
For a full, detailed list, view our report

Key Questions Answered in this Report
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Companies Mentioned

Eli Lilly and, Janssen, Novartis, Shire, Actavis, Alcobra, Amarantus, Boehringer Ingelheim, Concordia,Curemark, GlaxoSmithKline, Hisamitsu, Impax, Intellipharmaceutics, Mylan, Neurovance, Noven, Par Pharmaceuticals, Sanofi, Shionogi, Sunovion, Teva, Tris Pharma

Complete report is available @
http://www.reportstack.com/product/179769/global-adhd-drugs-market-2014-2018.html

Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604